Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer
Phase II study evaluates treatment for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive blood cancer
The antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) targets the CD123 antigen, which is overexpressed in BPDCN
PVEK monotherapy demonstrated strong responses, enabling ability to proceed with stem cell transplant for high-risk subgroup of patients with BPDCN
Seventy-five percent of patients...
First-in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma
The novel cell therapy, called RB-1355, appears safe and well tolerated
RB-1355 offers unique advantages, such as being ready in about one week...
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy
More than 90% of patients had a complete response to novel treatment combination
After two years, 97% of patients remained...
Dual-antigen targeting of large B-cell lymphoma shows promise in reducing relapse
Large B-cell lymphoma (LBCL) is an aggressive blood cancer with few treatment options
CAR T cell therapy targeting CD19 can work for patients with LBCL, but many relapse due to loss of CD19 expression
This Phase II trial explored a novel approach to target both CD19 and CD20 in LBCL treatment
More than 70% of patients had a complete response ...
